NeuroBo Pharmaceuticals announced dosing of the first patient in its two-part, Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist, for the treatment of nonalcoholic steatohepatitis, at The Pinnacle Edinberg/South Texas Research Institute in Edinburg, Texas, under the supervision of Principal Investigator, Dr. David Ramirez.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRBO:
- NeuroBo Pharmaceuticals names Hyung Heon Kim as CEO
- NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- NeuroBo Pharmaceuticals: First site IRB approval for Phase 2a trial of DA-1241
- NeuroBo Pharma enters term sheet with MThera Pharma to out-license NB-01
